BIO MEDICA LABORATORIES LIMITED

21 May 2026 - 25 May 2026 Individual Category SME NSE

Min Investment

₹278000

Price Band

₹132-₹139

Issue Size

₹52.43 Cr

Lot Size

1000 (per lot)

IPO Dates
img

21 May 2026

Open Date

img

25 May 2026

Close Date

img

26 May 2026

Allotment Date

img

29 May 2026

Listing Date

Know Before Investing

Strengths icon

  • Bio Medica manufactures generic injectable drugs for both human and veterinary use.
  • The company operates on a B2B contract manufacturing model with pharmaceutical companies.
  • Promoters have over 18 years of experience in the pharmaceutical sector.
  • The company offers liquid injections and dry powder injections in single and multi-dose formats.
  • Revenue and profitability improved significantly in FY25 compared to previous years.

Weaknesses icon

  • Production at Manufacturing Unit-I was suspended due to regulatory non-compliances.
  • The company operates from leased properties and does not own its manufacturing premises.
  • The business may face conflicts of interest with promoter group entities in similar businesses.
  • The company had a high debt-to-equity ratio in previous financial years.
  • Failure to renew or maintain licenses and approvals could affect operations.

About Bio Medica Laboratories Limited

Bio Medica Laboratories Limited is a pharmaceutical company engaged in the manufacturing of pharmaceutical parenteral formulations. The company manufactures generic injectable drugs, including liquid injections and dry powder injections, for both human and veterinary use. Its products are offered in single-dose and multi-dose formats to address a range of medical requirements. The company follows a business-to-business (B2B) model and primarily generates revenue through contract manufacturing arrangements with pharmaceutical companies. Under this model, Bio Medica manufactures formulations based on customer specifications, while the client company markets the products under its own brand name or as a technical collaborator. The company operates manufacturing facilities in Indore, Madhya Pradesh, and focuses on supplying formulations to other pharmaceutical businesses rather than directly selling to end consumers.

IPO Objectives

1. To meet out the Repayment of Loan;

2. Enhancement of its existing production capabilities by setting up of new manufacturing facility at theexisting premises

3. To meet out the General Corporate Purposes

Company Promoters

Mukesh Mehta

Pradeep Mehta

How to Apply for IPO

img img

Login

Login to your Bigul Account

Select Lots & Price

Choose the number of lots and price

UPI ID

Enter your UPI ID

UPI Mandate Request

A UPI Mandate Request Triggered

Approve Mandate

Approve the UPI Mandate Request

IPO Allotment

YES Share will be credited. and the amount will be debited

Close

Let's Open Free Demat Account